Quinestrol

Summary

Quinestrol (CHEMBL1201165) is an approved small-molecule xenoestrogen.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 364.5 Da · C25H32O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201165
Name	Quinestrol
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	9046
ChEBI	CHEBI:8716
Molecular formula	C25H32O2
Molecular weight	364.5
InChIKey	PWZUUYSISTUNDW-VAFBSOEGSA-N

SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)OC5CCCC5

IUPAC name: (8R,9S,13S,14S,17R)-3-cyclopentyloxy-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-ol

Pharmacological roles (ChEBI): xenoestrogen.

Also known as: Estrovis, NSC-759637, Quinestrol, W 3566, W-3566, SID11532988, SID29217904, SID56422146, QUINESTROL, SID144205893, SID170465054, quinestrol

Patent coverage: 1,029 distinct patent families (3,365 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 3,352 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 9 (assay-derived). Sample: Microtubule-associated protein tau, Streptokinase A, Prelamin-A/C, Glucocorticoid receptor, Estrogen receptor, Progesterone receptor, Lysosomal alpha-glucosidase, Androgen receptor, Mitogen-activated protein kinase 1.

Bioactivity

ChEMBL activities: 7 potent at pChembl ≥ 5 of 12 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
NR3C1	7.01	AC50	97	nM	CHEMBL_ACT_25175623
LMNA	6.95	Potency	112.2	nM	CHEMBL_ACT_3625693
PGR	6.66	AC50	221	nM	CHEMBL_ACT_25222845
LMNA	6.3	Potency	501.2	nM	CHEMBL_ACT_3632534
ESR1	6.21	AC50	611	nM	CHEMBL_ACT_25167101
P15207	5.77	AC50	1700	nM	CHEMBL_ACT_25187310
P10520	5.58	EC50	2605	nM	CHEMBL_ACT_4921596

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).